Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Overseas Clinical Trials of Ono's Elaspol Suspended
September 23, 2002
- OTC NEWS IN BRIEF
September 23, 2002
- Daiichi to Restructure Global R&D System
September 23, 2002
- PRESS SEMINAR
September 23, 2002
- Taisho Toyama Pharm to Be Created Next Month
September 23, 2002
- Orthopaedic Associations Launch Campaign to Prevent Fractures
September 23, 2002
- Initial Sales of Bisphosphonate Disappointing
September 23, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 23, 2002
- IFPW General Membership Meeting Held in Monte Carlo
September 23, 2002
- REGULATORY NEWS IN BRIEF
September 23, 2002
- PRESS SEMINAR
September 16, 2002
- OTC NEWS IN BRIEF
September 16, 2002
- Basic Policy for GL for Physician-led Clinical Trials Presented
September 16, 2002
- BULLETIN
September 16, 2002
- Nihon Schering Aims at \100 Billion Sales in 2010: Mr Martino
September 16, 2002
- DIAGNOSTIC NEWS IN BRIEF
September 16, 2002
- Fujisawa's Restructuring to Make Operating Profit Ratio Increase to 18-20% in 2005
September 16, 2002
- BUSINESS NEWS IN BRIEF
September 16, 2002
- JPMA President Calls For Joint Effort of Industry, Government Based on Vision
September 16, 2002
- Kuraya Sanseido Passive on Promoting Generics
September 16, 2002
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…